Results 181 to 190 of about 5,438,163 (262)
ABSTRACT Background Dysphagia is a common side‐effect after radiotherapy in head and neck cancer patients. This randomized study aimed to evaluate the effect of the shaker head‐lift exercise (HLE) after 12 months with flexible endoscopic evaluation of swallowing (FEES). Methods Patients were randomly assigned to the intervention (n = 30) or the control
Signe Rödseth Smith +3 more
wiley +1 more source
Achalasia and esophageal cancer: risks and links
Maura Torres-Aguilera,1 José María Remes Troche2 1Department of Pediatric Gastroenteritis, Hospital CMN “La Raza”, Mexico City, Mexico; 2Digestive Physiology and Motility Laboratory, Medical Biological Research Institute ...
Remes Troche JM, Torres-Aguilera M
core
ABSTRACT Background Frailty and sarcopenia may influence head and neck cancer (HNC) treatment outcomes, including dysphagia. Current understanding of this relationship, however, remains limited. This scoping review aimed to synthesize existing evidence on the relationship between frailty and/or sarcopenia and dysphagia in adults with HNC.
Rishni Perera +4 more
wiley +1 more source
Development and Preliminary Validation of a Modified Thyroid Symptom Questionnaire (TSQ)
ABSTRACT Background This study aimed to modify and validate the Thyroidectomy Voice and Symptom Questionnaire (TVSQ) to serve as a symptom screening tool in benign thyroid disease. Methods A 32‐item modified TVSQ was developed and administered alongside a symptom checklist to outpatients; controls were recruited to determine discriminative validity ...
Vikash Yogaraj +2 more
wiley +1 more source
What's New? This study introduces a novel approach for detecting locally advanced esophageal carcinoma using cell‐free DNA (cfDNA) analysis through a highly sensitive fragmentome assay. Unlike traditional sequencing‐based methods that are limited by the absence of specific mutations in esophageal tumors, our method offers an alternative by quantifying ...
Anouchka Modesto +21 more
wiley +1 more source
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt +7 more
wiley +1 more source
Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue +6 more
wiley +1 more source
ABSTRACT Long‐term survival data for patients with locally advanced gastro‐esophageal adenocarcinoma (GEA) treated with neoadjuvant chemoimmunotherapy are lacking. We describe the long‐term disease‐free survival (DFS) and overall survival (OS) outcomes of such patients treated with a novel neoadjuvant chemoimmunotherapy regimen, aDCF (avelumab with ...
Thierry Alcindor +8 more
wiley +1 more source
ABSTRACT Gastrointestinal (GI) cancers, including esophageal (EC), gastric (GC), and colorectal cancer (CRC), impose a substantial global burden, with early detection remaining crucial for improving patient outcomes. The oral and gut microbiota are increasingly implicated in cancer development and hold promise as sources of non‐invasive biomarkers ...
Saidi Hu +12 more
wiley +1 more source
Combined airway and esophageal stents implantation for malignant tracheobronchial and esophageal disease: A STROBE-compliant article. [PDF]
Bi Y, Ren J, Chen H, Bai L, Han X, Wu G.
europepmc +1 more source

